Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.

PURPOSE To find predictors for rectal and intestinal acute toxicity in patients with prostate cancer treated with > or =70 Gy conformal radiotherapy. METHODS AND MATERIALS Between July 2002 and March 2004, 1,132 patients were entered into a cooperative study (AIROPROS01-02). Toxicity was scored using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale and by considering the changes (before and after treatment) of the scores of a self-administered questionnaire on rectal/intestinal toxicity. The correlation with a number of parameters was assessed by univariate and multivariate analyses. Concerning the questionnaire, only moderate/severe complications were considered. RESULTS Of 1,132 patients, 1,123 were evaluable. Of these patients, 375, 265, and 28 had Grade 1, 2, and 3 Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicity, respectively. The mean rectal dose was the most predictive parameter (p = 0.0004; odds ratio, 1.035) for Grade 2 or worse toxicity, and the use of anticoagulants/antiaggregants (p = 0.02; odds ratio, 0.63) and hormonal therapy (p = 0.04, odds ratio, 0.65) were protective. The questionnaire-based scoring revealed that a greater mean rectal dose was associated with a greater risk of bleeding; larger irradiated volumes were associated with frequency, tenesmus, incontinence, and bleeding; hormonal therapy was protective against frequency and tenesmus; hemorrhoids were associated with a greater risk of tenesmus and bleeding; and diabetes associated highly with diarrhea. CONCLUSION The mean rectal dose correlated with acute rectal/intestinal toxicity in three-dimensional conformal radiotherapy for prostate cancer, and hormonal therapy and the use of anticoagulants/antiaggregants were protective. According to the moderate/severe injury scores on the self-assessed questionnaire, several clinical and dose-volume parameters were independently predictive for particular symptoms.

[1]  G. Gustafson,et al.  Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[2]  Franca Foppiano,et al.  Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  J. Denham,et al.  Is there more than one late radiation proctitis syndrome? , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Franca Foppiano,et al.  The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). , 2003, International journal of radiation oncology, biology, physics.

[5]  H. Sandler,et al.  RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? , 2003, International journal of radiation oncology, biology, physics.

[6]  S. Fosså,et al.  Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  James A. Purdy,et al.  Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. , 2000, International journal of radiation oncology, biology, physics.

[8]  C. Ling,et al.  Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. , 2000, International journal of radiation oncology, biology, physics.

[9]  W. Dörr,et al.  Consequential late effects in normal tissues. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  J. Manola,et al.  Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. , 2005, Urologic oncology.

[11]  A. Markoe,et al.  Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. , 2002, Seminars in radiation oncology.

[12]  G. Sanguineti,et al.  Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Ronald C. Chen,et al.  Time course and predictors of symptoms after primary prostate cancer therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Nahum,et al.  A cylindrical model of the rectum: comparing dose-volume, dose-surface and dose-wall histograms in the radiotherapy of prostate cancer. , 2003, Physics in medicine and biology.

[15]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[16]  P. Koper,et al.  Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. , 2005, International journal of radiation oncology, biology, physics.

[17]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[18]  M. Hauer-Jensen,et al.  The radiotherapeutic injury--a complex 'wound'. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  C. N. Coleman,et al.  Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. , 2005, International journal of radiation oncology, biology, physics.

[20]  S. Fosså,et al.  Changes in Treatment Volume of Hormonally Treated and Untreated Cancerous Prostate and its Impact on Rectal Dose , 2003, Acta oncologica.

[21]  J. Loeffler,et al.  The effect of nonmalignant systemic disease on tolerance to radiation therapy. , 2002, The oncologist.

[22]  Franca Foppiano,et al.  Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. , 2003, International journal of radiation oncology, biology, physics.

[23]  George Starkschall,et al.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[24]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[25]  F Foppiano,et al.  Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  G E Hanks,et al.  The effect of dose on local control of prostate cancer. , 1988, International journal of radiation oncology, biology, physics.

[27]  L. Muren,et al.  Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  Patrick A Kupelian,et al.  Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[29]  Riccardo Calandrino,et al.  Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). , 2002, International journal of radiation oncology, biology, physics.

[30]  A Pollack,et al.  Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. , 2000, International journal of radiation oncology, biology, physics.

[31]  Jeff M Michalski,et al.  Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. , 2005, International journal of radiation oncology, biology, physics.

[32]  M. Hoogeman,et al.  Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. , 2005, International journal of radiation oncology, biology, physics.

[33]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[34]  F. Calvo,et al.  Preliminary report of a multicenter spanish trial (GICOR 05) of risk-adapted androgen ablation combined with dose-escalation 3D conformal therapy for prostate cancer: impact on early toxicity , 2003 .

[35]  Feliciano García-Vicente,et al.  Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. , 2003, International journal of radiation oncology, biology, physics.

[36]  Richard K Valicenti,et al.  Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. , 2004, International journal of radiation oncology, biology, physics.

[37]  M. Zelefsky,et al.  Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. , 1997, Urology.

[38]  Srinivasan Vijayakumar,et al.  Self-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bother of symptoms. , 1999, Urology.

[39]  A. Zietman,et al.  The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. , 1995, International journal of radiation oncology, biology, physics.

[40]  P. Rust,et al.  Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  M. Keyes,et al.  Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[42]  A. Hanlon,et al.  Diabetes mellitus: a predictor for late radiation morbidity. , 1999, International journal of radiation oncology, biology, physics.

[43]  R. Pötter,et al.  Acute Side Effects during 3-D-Planned Conformal Radiotherapy of Prostate Cancer , 2003, Strahlentherapie und Onkologie (Print).